Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2753314 | 0.84 | IDO1 (0.40) | CYP2A6IDO1TSHRCYP2D6SCN9A | |
| SCHEMBL3537077 | 0.81 | CYP2A6 (0.36) | CYP2A6HSD11B1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1368412 | 0.80 | ALDH1A1 (0.41) | CYP2A6HPGDDPP4ALDH1A1BACE1 | |
| SCHEMBL2750535 | 0.79 | IDO1 (0.39) | CYP2A6IDO1RAB9ATP53TSHR | |
| SCHEMBL2751781 | 0.79 | AHR (0.50) | HSD11B1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2448737 | 0.78 | ALDH1A1 (0.39) | CYP2A6NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL5924613 | 0.78 | CYP2A6 (0.56) | CYP2A6MAOBNPC1RAB9ASMN1; SMN2 | |
| Water SCHEMBL9550934 | 0.77 | CYP2A6 (0.94) | CYP2A6MAOBHSD11B1NPC1RAB9A | |
| SCHEMBL2752419 | 0.77 | GRIA1 (0.34) | CYP2A6LMNATSHRCYP1A2 | |
| SCHEMBL2183931 | 0.76 | GSK3B (0.40) | CYP2A6IDO1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324924-B1 | NOVEL SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | DSM IP ASSETS BV (NL) | 2019-08-21 | — | — | EP | claimed |
| US-9403807-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150284376-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8158641-B2 | 2-anilino-4-aminoalkyleneaminopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8026258-B2 | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| US-5194441-A | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | CYP2A6 2564/4885MAOB 1114/4885IDO1 234/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | CYP2A6 2564/4885MAOB 1114/4885IDO1 234/4885 |
| US-20150284376-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, CYP21A2 | CYP2A6 166/4885MAOB 1048/4885IDO1 3667/4885 |
| US-20100120845-A1 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | CMBL, ALK, ALKBH1 | CYP2A6 659/4885MAOB 188/4885IDO1 980/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | CYP2A6 2073/4885MAOB 1202/4885IDO1 574/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | CYP2A6 1889/4885MAOB 1120/4885IDO1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.